Loading institutional data...
Loading institutional data...
Held by 301 of 5,944 reporting institutions (94th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $18.28 today, the market must believe free cash flow compounds 13.0%/yr for a decade (off $272M normalized FCF).
The market's 13.0% is more optimistic than its 8-yr track record.
2-stage DCF · 0.31B shares · net debt $2.3B
mean 181.6% · volatility σ 591% · implied rate exceeded in 2/7 yrs
Central path = implied 13.0%/yr growth; shaded band = ±1σ (591%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $270M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 3%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $282M covers all $36M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2020-01-31 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash of $282M fully covers short-term debt of $7M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 10-yr range · 90th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 10-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 7.2× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 56.5 | 70.5 | 66.7 | 63.3 | 64.5 | 65.7 | 63.5 | 63.1 |
| Gross Profit | 43.1 | 21.7 | 31.5 | 36.7 | 35.5 | 34.3 | 36.5 | 36.9 |
| R&D | 11.7 | 11.6 | 9.0 | 9.6 | 8.8 | 6.8 | 6.8 | 6.2 |
| SG&A | 13.7 | 17.8 | 16.4 | 17.5 | 18.1 | 18.0 | 17.1 | 17.5 |
| Operating Income | -1.2 | -15.3 | 4.6 | 7.3 | -4.3 | 8.5 | 8.9 | 13.1 |
| Income Tax | -0.1 | 23.6 | -5.2 | 0.5 | 0.3 | 0.4 | 0.7 | 0.4 |
| Net Income | -1.2 | -37.1 | 3.4 | 0.6 | -12.2 | -3.5 | -4.2 | 2.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on AMRX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02B 100.0% | $2.79B 100.0% | $2.39B 100.0% | $2.21B 100.0% | $2.09B 100.0% | $1.99B 100.0% | $1.63B 100.0% | $1.66B 100.0% | $1.03B 100.0% | $1.02B 100.0% |
| Cost of Revenue | $1.91B 63.1% | $1.77B 63.5% | $1.57B 65.7% | $1.43B 64.5% | $1.32B 63.3% | $1.33B 66.7% | $1.15B 70.5% | $938.8M 56.5% | $507.5M 49.1% | $420.8M 41.3% |
| Gross Profit | $1.11B 36.9% | $1.02B 36.5% | $820.6M 34.3% | $784.7M 35.5% | $769.0M 36.7% | $628.4M 31.5% | $353.0M 21.7% | $716.4M 43.1% | $526.2M 50.9% | $597.5M 58.7% |
| Research & Development | $186.2M 6.2% | $190.7M 6.8% | $163.9M 6.8% | $195.7M 8.8% | $201.8M 9.6% | $179.9M 9.0% | $188.0M 11.6% | $194.2M 11.7% | $171.4M 16.6% | $179.0M 17.6% |
| Selling, General & Admin | $526.8M 17.5% | $476.4M 17.1% | $429.7M 18.0% | $399.7M 18.1% | $365.5M 17.5% | $326.7M 16.4% | $289.6M 17.8% | $227.8M 13.7% | $109.0M 10.5% | $118.8M 11.7% |
| Operating Income | $394.1M 13.1% | $249.3M 8.9% | $204.4M 8.5% | -$94.9M -4.3% | $152.7M 7.3% | $91.2M 4.6% | -$248.7M -15.3% | -$19.7M -1.2% | $245.1M 23.7% | $284.9M 28.0% |
| Other Income (Expense), net | -$254.9M -8.4% | -$304.3M -10.9% | -$244.6M -10.2% | -$153.2M -6.9% | -$121.3M -5.8% | -$126.9M -6.4% | $28.4M 1.7% | -$183.0M -11.0% | -$73.8M -7.1% | -$70.1M -6.9% |
| Pretax Income | $139.2M 4.6% | -$55.0M -2.0% | -$40.3M -1.7% | -$248.1M -11.2% | $31.4M 1.5% | -$35.8M -1.8% | -$220.2M -13.5% | -$202.7M -12.2% | $171.3M 16.6% | $214.8M 21.1% |
| Income Tax Expense | $11.3M 0.4% | $18.9M 0.7% | $8.5M 0.4% | $6.7M 0.3% | $11.2M 0.5% | -$104.4M -5.2% | $383.3M 23.6% | -$1.4M -0.1% | $2.0M 0.2% | $5.4M 0.5% |
| Net Income | $72.1M 2.4% | -$116.9M -4.2% | -$84.0M -3.5% | -$270.6M -12.2% | $13.2M 0.6% | $67.8M 3.4% | -$603.6M -37.1% | -$19.7M -1.2% | $0 0.0% | $0 0.0% |
| Per Share | ||||||||||
| EPS (Basic) | $0.23 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.62 | $-2.74 | $-0.16 | — | — |
| EPS (Diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.61 | $-2.74 | $-0.16 | — | — |
| Weighted Avg Shares (Basic) | 313.4M | 309.0M | 176.1M | 150.9M | 148.9M | 147.4M | 132.1M | 127.3M | — | — |
| Weighted Avg Shares (Diluted) | 324.8M | 309.0M | 176.1M | 150.9M | 151.8M | 148.9M | 132.1M | 127.3M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| AMRX | $5.7B | 83.1× | 17.8× | 1.9× | 8.0% | 36.9% | 2.4% | -102% | 2.9% | 5.7× | 301 |
Peers = companies sharing AMRX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.